TrialRevista do Instituto de Medicina Tropical de Sao Paulo2025

Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals.

Karina Takesaki Miyaji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.